Sodium pyrophosphate decahydrate 20mg kit for radiopharmaceutical preparation
Requires a prescription from a doctor or prescriber
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Sodium pyrophosphate decahydrate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Sodium pyrophosphate decahydrate on the MHRA register
Technescan PYP kit for radiopharmaceutical preparation
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 18 studies.
2019–2026
Showing all 18 studies, sorted by most relevant.
Yan Wang, K. Yu, Hao Peng, et al.
Energy, 2019
Rui Huang, Jinxin Feng, Ziye Ling, et al.
Construction and Building Materials, 2019
Yulia S. Lukina, S. Kotov, Leonid L. Bionyshev-Abramov, et al.
Ceramics, 2023
Low-temperature ceramics based on magnesium calcium phosphate cement are a promising resorbable material for bone tissue restoration with the possibility of functionalization. The replacement of the magnesium Mg2+ ion with a calcium Ca2+ ion at the stage of preparation of the precursor leads to the production of multiphase ceramics containing phases of brushite, monetite, and newberyite, with different dissolution rates. Multiphase ceramics leads to volumetric resorption with preservation of their geometric shape, which was confirmed by the results of an evaluation of the output of magnesium Mg2+ and calcium Ca2+ ions into the contact solution of the ceramics and the X-ray density of ceramic samples during subcutaneous implantation. The combined introduction of sodium pyrophosphate decahydrate and citric acid monohydrate as setting inhibitors neutralizes their insignificant negative effect on the physico-chemical properties of ceramics (strength, pH, porosity), determining the optimal composition. In vivo experiments with setting inhibitors in the composition of ceramics showed a different biological response, affecting the rate of resorption on par with magnesium ions. Preliminary data on biocompatibility and solubility determined magnesium-calcium phosphate ceramics containing additives that regulate setting to be a potential material for bone tissue restoration and a vector for further research, including in orthotopic implantation models.
Abstract licence: CC BY
S. Mohamed Illyas, A. MuthuManokar, A.E. Kabeel, et al.
Thermal Science and Engineering Progress, 2025
Kowalski P, Hermann N, Kroll D, et al.
2024
- Norepinephrine
- Solid Phase Extraction
- Liquid-Liquid Extraction
The measurement of selected norepinephrine metabolites, such as 3,4-dihydroxyphenylglycol (DHPG), 3-methoxy-4-hydroxyphenylethylenglycol (MHPG), and vanillylmandelic acid (VMA), in biological matrices—including urine—is of great clinical importance for the diagnosis and monitoring of diseases. This fact has forced researchers to evaluate new analytical methodologies for their isolation and preconcentration from biological samples. In this study, the three most popular extraction techniques—liquid-liquid extraction (LLE), solid-phase extraction (SPE), and a new 3D-printed system for dispersive solid-phase extraction (3D-DSPE)—were investigated. Micellar electrokinetic chromatography (MEKC) with a diode array detector (DAD) at 200 nm wavelength was applied to the separation of analytes, allowing for the assessment of the extraction efficiency (R) and enrichment factor (EF) for the tested extraction types. The separation buffer (BGE) consisted of 5 mM sodium tetraborate decahydrate, 50 mM SDS, 15% (v/v) MeOH, 150 mM boric acid, and 1 mM of 1-hexyl-3-methylimidazolium chloride (the apparent pH of the BGE equaled 7.3). The EF for each extraction procedure was calculated with respect to standard mixtures of the analytes at the same concentration levels. The 3D-DSPE procedure, using DVB sorbent and acetone as the desorption solvent, proved to be the most effective approach for the simultaneous extraction and determination of the chosen compounds, achieving over 3-fold signal amplification for DHPG and MHPG and over 2-fold for VMA. Moreover, all extraction protocols used for the selected norepinephrine metabolites were estimated and discussed. It was also confirmed that the 3D-DSPE-MEKC approach could be considered an effective tool for sample pretreatment and separation of chosen endogenous analytes in urine samples.
Abstract licence: CC BY
Uehara Y, Shimamura Y, Takemura C, et al.
2025
<p>The effect of cosmetic ingredients on growth and virulence factor expression in <italic>Staphylococcus aureus</italic> may vary between culture medium and skin. Researchers have used an <italic>in vitro</italic> skin model with human heel callus to assess bacterial survival and growth on the stratum corneum of the epidermis. Here, we reconstituted a skin model using keratin as a base (instead of callus) and compared it with brain heart infusion (BHI) medium. We investigated the effects of five cosmetic ingredients (macadamia nut oil, sodium myristoyl methyl taurate, methyl <italic>p</italic>-hydroxybenzoate, 2-phenoxyethanol, and zinc oxide) on growth and virulence factor expression in <italic>S. aureus</italic>. Interestingly, the survival pattern of <italic>S</italic>. <italic>aureus</italic> in our skin model was similar to that reported in models using callus. Upon the addition of cosmetic ingredients to BHI or skin model medium, the sensitivity of <italic>S. aureus</italic> to these cosmetic ingredients differed between the two media. Notably, after adding the two tested cosmetic ingredients, the expression level of staphylococcal enterotoxin A in <italic>S. aureus</italic> reduced significantly in skin model medium compared with that in the BHI medium. Additionally, the expression levels of other <italic>S. aureus</italic> virulence factors (RNAIII, <italic>icaA</italic>, and <italic>hlb</italic>) differed between the two media. These findings suggest that our skin model is a valuable tool for evaluating the effects of cosmetic ingredients on growth and virulence factor expression in <italic>S. aureus</italic>.</p>
Abstract licence: CC BY
Roca S, Leclercq L, Gonzalez P, et al.
2025
- Electrophoresis, Capillary
- Calibration
- Equipment Design
ABSTRACT In this work, we describe an optical setup to determine the internal diameter of narrow bore fused silica capillary used in capillary electrophoresis and Taylor dispersion analysis (TDA). Indeed, fluctuations up to about ±3–4 µm on the capillary I.D. can generate important inaccuracy on the hydrodynamic radius determination by TDA. Calibration of the optical set‐up, impact of the operator and of the placement of the capillary in the focal plane, and the influence of the way to cut the capillary were investigated and discussed. This optical set‐up was next used to determine capillary I.D. on a 60 m long capillary spool. Relatively small variations were observed along a 60 m capillary spool (0.3 µm maximum variation), while important I.D. fluctuations can be observed from capillary batch to batch. Taking three capillaries of three different nominal I.D. values, R h values of sodium benzoate obtained by TDA were not significantly different if the capillary I.D. were optically measured, while significant variations were observed with the nominal I.D. values. A protocol based on TDA of sodium benzoate was proposed for calibrating narrow bore fused silica capillary I.D. without the use of optical measurements for researchers that would not have access to such optical equipment.
Abstract licence: CC BY
DONG Xuan, LU Ruqing, PANG Xiaoyang, WANG Yunna, LÜ Jiaping, LI Hongjuan, ZHANG Shuwen
Shipin Kexue, 2026
This study investigated the hydrothermal phosphorylation modification of whey protein isolate (WPI90) using mixtures of sodium hexametaphosphate (SHMP) and tetrasodium pyrophosphate decahydrate (SPP) at different mass ratios (1:1, 1:2, and 2:1) applied at varying mass concentrations (0.03, 0.06, and 0.09 g/100 mL). The secondary structure, thermal stability, solubility, foaming properties, emulsifying properties, and water-holding capacity of WPI were determined before and after phosphorylation. The results indicated that the negative charges introduced by phosphorylation altered the structural characteristics of WPI. This modification resulted in an increase in α-helix content in the secondary structure and induced noticeable microstructural changes. Phosphate addition enhanced the thermal stability and kinetic stability after heating to varying degrees; the phosphorylated WPI solutions remained clear and transparent after heating, showing a turbidity approximately 80% lower than that of unmodified WPI90. All phosphorylation modifications altered the foaming and emulsifying properties of WPI. Notably, the addition of the 2:1 mixture at 0.06 and 0.09 g/100 mL resulted in a 3- to 4-fold increase in the emulsion stability of WPI and increased the water-holding capacity from 20% to 50% and 90%, respectively, demonstrating a remarkable modification effect. This study provides a feasible approach to address the stability limitations of WPI in food processing.
Abstract licence: CC BY-SA
Yuto Zushi, Shun Iwasaki, Nobuyoshi Koga
2023
Pagliaro M, Petri GL, Angellotti G, et al.
2026
- Borates
- Antioxidants
An important micronutrient exerting multiple health benefits, boron is a trace element with high potential for the treatment of neurodegenerative disease, allergic diseases, and cancer. Biochemistry and biomedical studies restarted in the early 1990s first unveiled antioxidant, anti-inflammatory, nootropic, anticancer, and antigenotoxic properties of borates including borax (sodium tetraborate decahydrate), boric acid and boron esters at low dosage, and then clearly established hormetic response of these compounds. New clinical studies conducted in the last 5 years (2020-2025) identified new potential use of borates in biomedicine and nutraceuticals, ranging from dietary supplement for bone, joint, and hormone health through new treatments for diabetic foot ulcer. The study offers a critical retrospective analysis of borates in biomedicine starting from Lister's discovery of boric acid powerful antiseptic properties in 1875. The analysis teaches an important lesson to researchers working at identifying novel therapeutic agents and to research policy managers.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.